Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 6/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16975340 | 0.95 | MTOR (0.38) | — | |
| SCHEMBL16975261 | 0.87 | ABL1 (0.40) | ABL1PIK3CDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16975481 | 0.86 | ABL1 (0.40) | ABL1PIK3CDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16975328 | 0.83 | MTOR (0.37) | ABL1PIK3CDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16975298 | 0.83 | ABL1 (0.52) | ABL1PIK3CDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16975300 | 0.82 | MTOR (0.37) | ABL1PIK3CDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16975352 | 0.82 | MAPK1 (0.42) | ABL1PIK3CAPIK3CG | |
| SCHEMBL16975323 | 0.82 | BRD4 (0.38) | — | |
| SCHEMBL16975240 | 0.81 | ABL1 (0.36) | ABL1PIK3CDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16975327 | 0.81 | JAK2 (0.36) | ABL1PIK3CDNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170007615-A1 | Antibacterial Compounds | SPERO GYRASE, INC. | 2017-01-12 | — | — | US | claimed |
| EP-3102203-A2 | ANTIBACTERIAL COMBINATIONS COMPRISING POLYMYXIN | SPERO GYRASE, INC. (US) | 2016-12-14 | — | — | EP | claimed |
| WO-2015114452-A2 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD (GB) | 2015-08-06 | — | — | WO | claimed |
| US-20170007615-A1 | Antibacterial Compounds | SPERO GYRASE, INC. | 2017-01-12 | — | — | US | disclosed |
| EP-3102203-A2 | ANTIBACTERIAL COMBINATIONS COMPRISING POLYMYXIN | SPERO GYRASE, INC. (US) | 2016-12-14 | — | — | EP | disclosed |
| WO-2015114452-A2 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD (GB) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170007615-A1 | Antibacterial Compounds | CLPP, MRPL21, RELA | ABL1 294/4885PIK3CD 442/4885NPC1 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.